Group 1 - The PIONEER TAVR® system developed by CoKai (Nantong) Life Sciences has received approval from the National Medical Products Administration (NMPA) in China, marking a significant innovation in the field of interventional treatment for structural heart diseases [2] - The PIONEER TAVR® system provides a new treatment option for patients with severe aortic regurgitation (AR), particularly for those who are elderly or have other health issues that prevent them from undergoing traditional surgical procedures [2][5] - The system consists of three components: the aortic valve, the delivery system, and the valve loading device, designed specifically for high-risk AR patients [6][9] Group 2 - The PIONEER TAVR® system features innovative three-dimensional bending technology that allows for precise positioning and release during the procedure, ensuring optimal valve placement [8] - The system is designed for patients aged 70 and above with severe AR who cannot tolerate conventional surgery, offering a minimally invasive treatment alternative [8][10] - Clinical studies led by West China Hospital of Sichuan University involved 110 high-risk AR patients, demonstrating significant safety and efficacy of the PIONEER TAVR® system [10][12] Group 3 - The clinical study results showed a 99% technical success rate and a 97.27% device success rate within 30 days post-operation, with no moderate or severe paravalvular leaks reported [14] - One-year follow-up indicated an all-cause mortality rate of 2.7%, with no acute kidney injury or coronary artery obstruction observed, highlighting the system's advantages over traditional surgical methods [14][17] - The hemodynamic performance of the valve remained stable, with an effective orifice area of 2.05 cm² at one year, indicating long-term stability of the valve implantation [21] Group 4 - CoKai Life Sciences, established in 2018 and headquartered in Nantong, Jiangsu Province, focuses on innovative devices for treating structural heart diseases and aims to lead the domestic market while expanding globally [19] - The company has achieved significant breakthroughs in cardiac intervention, particularly in the development of transcatheter mitral valve repair systems and balloon dilation devices, showcasing strong technical innovation and market competitiveness [19]

Core Viewpoint - The company anticipates achieving revenue of approximately RMB 90 million to 92 million for the fiscal year ending December 31, 2025, with total income and gains expected to reach around RMB 105 million to 110 million, marking a significant achievement in its first commercial year [1] Group 1 - The company's first commercial product, the Ken-Valve aortic valve system, has generated robust revenue in its inaugural year, attributed to its design and operational advantages that facilitate rapid adoption across various healthcare institutions [1] - The company has initiated paid clinical implantations of multiple structural heart intervention products overseas, receiving high praise from key opinion leaders and experts globally, addressing the long-standing unmet clinical needs in structural heart disease [1] Group 2 - The company plans to continue advancing multiple product pipelines and deepen its international strategic layout in 2026 to achieve rapid revenue growth [1] - Efforts will be made to enhance management efficiency and reduce operational costs across production, supply chain, marketing, and operational management to meet long-term strategic development goals [1]

太平医疗健康基金表示："太平医疗健康基金投资实践中始终坚持研究先行，持续聚焦全球最具创新性 和竞争潜力的产品。汇禾医疗以K-Clip®为代表原始创新介入医疗器械，开创了三尖瓣瓣环成型修复的 全新术式，未来有望成为全球范围内具备商业化能力的三尖瓣环缩修复产品。期待汇禾医疗凭借'瓣环 修复技术'和'一瓣双修理念'持续迭代研发，服务全球患者。" 夏尔巴投资创始管理合伙人蔡大庆表示："本轮融资的完成，将为汇禾医疗的产品商业化提供充足的资 金保障、丰富的保险渠道和医疗机构资源，加速K-Clip®等产品在中国及海外市场的推广和应用，为公 司的业绩增长奠定坚实基础。夏尔巴持续看好汇禾医疗的研发能力及商业化前景，自首次投资后也坚定 的多次追加投资。" 汇禾医疗董事长林林表示："汇禾医疗完成D轮融资，是太平医疗健康基金在结构性心脏病介入治疗领 域的重要布局，也是保险资金服务新质生产力发展、支持科技自立自强的生动实践。为公司的商业化进 程和全球化发展注入强劲动力。同时，也感谢老股东夏尔巴对汇禾医疗长期坚定的支持和认可。汇禾医 疗将继续在心血管介入领域不断突破创新，为患者带来更微创、更安全的治疗方案，为医生提供更简 便、更可控的手 ...

Core Insights - Chinese research team showcased innovative cardiac intervention device at the global transcatheter cardiovascular therapy conference in San Francisco, indicating China's shift from "follower" to "leader" in structural heart disease intervention [1] Group 1: Clinical Data and Innovation - The "J-VALVE TF transcatheter aortic valve system" demonstrated superior clinical outcomes, including lower rates of post-operative cardiac mortality and third-degree atrioventricular block compared to international counterparts [1] - The device features a unique patented "movable positioning component" that addresses key challenges in treating aortic regurgitation, such as valve anchoring difficulties and high rates of paravalvular leak [1] Group 2: Conference Overview - The conference, hosted by the American College of Cardiology, is one of the largest and most influential academic meetings in the field of transcatheter cardiovascular interventions, attracting over ten thousand participants from more than 100 countries and regions [2]

Group 1 - The article highlights the presentation of new clinical data for a medical device treating aortic regurgitation by a Chinese research team at the global transcatheter cardiovascular therapy conference in San Francisco [1] - The "J-VALVE TF transcatheter aortic valve system" demonstrates superior clinical outcomes, including lower rates of cardiac mortality and third-degree atrioventricular block compared to international counterparts, indicating its effectiveness and safety [1] - The innovative design of the "J-VALVE TF valve" addresses key challenges in treating regurgitation, such as anchoring difficulties and high rates of paravalvular leak and pacemaker implantation [1] Group 2 - The conference is one of the largest and most influential transcatheter cardiovascular intervention academic meetings globally, attended by over ten thousand cardiologists and researchers from more than 100 countries and regions [2]

Core Viewpoint - Beijing Bairen Medical Technology Co., Ltd. has had its application for the registration of a patent foramen ovale (PFO) occluder accepted by the National Medical Products Administration, indicating a significant step in the development of this medical device [1][3]. Group 1: Product Information - The PFO occluder is a self-expanding, mushroom-shaped implant made from nickel-titanium alloy wire, designed to close the abnormal shunt caused by a patent foramen ovale [3]. - The device is intended to prevent complications associated with PFO, such as unexplained strokes and migraines, by effectively blocking the passage between the heart's atria [2][3]. - Clinical studies have shown that the PFO occluder can significantly reduce or eliminate migraine attacks, highlighting its therapeutic potential [2]. Group 2: Market Potential - The incidence of PFO in the general population ranges from 22% to 38%, with rates as high as 32% to 50% in patients with unexplained ischemic strokes, indicating a substantial patient base for the PFO occluder [2]. - The market for PFO occluders is expected to continue growing, with the number of implants increasing from 21,000 in 2021 to an estimated 54,000 by 2024, reflecting a strong demand for this treatment option [2]. Group 3: Regulatory Status - The acceptance of the registration application for the PFO occluder does not guarantee approval, and the company acknowledges the uncertainty regarding the impact of this product on its future performance [3].

Core Viewpoint - Beijing Bairen Medical Technology Co., Ltd. has announced that its application for the registration of a patent foramen ovale (PFO) occluder has been officially accepted by the National Medical Products Administration, indicating progress in the development of this medical device [1]. Group 1: Product Information - The application pertains to a Class III medical device, specifically a PFO occluder, with acceptance number CQZ2501513 [1]. - PFO is a physiological channel left over from embryonic heart septum development, which can lead to various health issues, including unexplained strokes and migraines [1][2]. - The PFO occluder is designed as a self-expanding mushroom-shaped implant made from nickel-titanium alloy wire, lined with a PET polyester membrane, which effectively closes the abnormal shunt [3]. Group 2: Market Potential - The incidence of PFO in the general population ranges from 22% to 38%, and it is found in 32% to 50% of patients with unexplained ischemic strokes [2]. - The market for PFO occluders is expected to continue growing, with increasing recognition of their effectiveness in preventing strokes and reducing migraine symptoms [2][3]. - The product's safety and efficacy have been confirmed through preclinical studies and clinical trials, meeting clinical usage requirements [3].

Core Viewpoint - The company reported a revenue of RMB 471 million for the fiscal year ending December 31, 2024, while focusing on the structural heart disease sector and enhancing its clinical development pipeline [1] Group 1: Financial Performance - The company achieved a revenue of RMB 471 million during the reporting period [1] Group 2: Product Development and Clinical Trials - The company has established a product pipeline consisting of ten innovative devices targeting heart valve diseases, with a focus on interventional treatments [2] - The product lineup includes four commercialized TAVR products and one TPVR product, along with two catheter-based surgical accessories [2] - Clinical trials are ongoing for new generation TAVR products and innovative devices that can be used for both TMVR and TTVR [2] Group 3: Clinical Milestones - The company has made significant progress in global clinical research projects, achieving multiple important milestones [1] - The first self-expanding TAVR product, Venus-PowerX, and the first balloon-expandable TAVR product, Venus-Vitae, have commenced clinical trials [1] - The Cardiovalve product has shown excellent safety and efficacy in key clinical studies in Europe, receiving positive feedback from overseas experts [1]